RU95104501A - Antilymphoglob - Google Patents

Antilymphoglob

Info

Publication number
RU95104501A
RU95104501A RU95104501/14A RU95104501A RU95104501A RU 95104501 A RU95104501 A RU 95104501A RU 95104501/14 A RU95104501/14 A RU 95104501/14A RU 95104501 A RU95104501 A RU 95104501A RU 95104501 A RU95104501 A RU 95104501A
Authority
RU
Russia
Prior art keywords
solution
globulin
vinylpyridine
drops
poly
Prior art date
Application number
RU95104501/14A
Other languages
Russian (ru)
Inventor
Л.И. Кириллов
Original Assignee
Л.И. Кириллов
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Л.И. Кириллов filed Critical Л.И. Кириллов
Priority to RU95104501/14A priority Critical patent/RU95104501A/en
Publication of RU95104501A publication Critical patent/RU95104501A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

FIELD: medicine. SUBSTANCE: antilymphoglob is 0.002-0.003% solution of anti-T-lymphocyte gamma-globulin and 2% solution of poly-4-vinylpyridine. Agent can be used for prevention of the transplanted organs and tissues detachment, treatment patients with AIDS and activation of protective function of organism immunological system. Agent does not contain blood serum albumin that causes allergic reactions and does not decrease protective function of organism immunological system. Solution of anti-T-lymphocyte gamma-globulin (concentration is 0.002-0.003%) is administrated intravenously at dose 1-4 ml/1 kg weight at rate 20 drops/min with simultaneous intravenous administration of 2% solution of poly-4-vinylpyridine at rate 20 drops/min (1 ml/1 kg weight). The repeated course - in 2 months. The amount of the administrated antilymphocyte globulin depends on the aim of gamma-globulin administration. EFFECT: enhanced effectiveness of agent.

Claims (1)

Антилимфоглоб представляет 0,002-0,003% раствор анти-Т-лимфоцитарного гамма-глобулина и 2% раствор поли-4-винилпиридина. Предназначен для предупреждения отторжения пересаженных органов и тканей, лечения больных СПИДом и активизации защитной функции иммунологической системы организма. Отличается тем, что не содержит сывороточного альбумина крови, вызывающего аллергические реакции, и не понижает защитной функции иммунологической системы организма. 0,002-0,003% раствор анти-Т-лимфоцитарного гамма-глобулина вводится внутривенно по 1-4 мл на 1 кг веса по 20 кап. в мин одновременным введением внутривенно 2%-ного раствора поли-4-винилпиридина по 20 кап. в мин по 1 мл на 1 кг веса. Повторный курс через 2 мес. Количество введения антилимероцитарного глобулина зависит от того, с какой целью гамма-глобулин вводится.Antilimphoglob is a 0.002-0.003% solution of anti-T-lymphocytic gamma globulin and a 2% solution of poly-4-vinylpyridine. Designed to prevent rejection of transplanted organs and tissues, treat AIDS patients and enhance the protective function of the body's immunological system. It differs in that it does not contain serum albumin of the blood, which causes allergic reactions, and does not lower the protective function of the body's immunological system. 0.002-0.003% solution of anti-T-lymphocytic gamma globulin is administered intravenously in 1-4 ml per 1 kg of body weight in 20 drops. per minute by simultaneous intravenous administration of a 2% solution of poly-4-vinylpyridine in 20 drops. per minute, 1 ml per 1 kg of weight. Repeated course after 2 months. The amount of administration of antilimerocytic globulin depends on the purpose for which gamma globulin is administered.
RU95104501/14A 1995-03-28 1995-03-28 Antilymphoglob RU95104501A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU95104501/14A RU95104501A (en) 1995-03-28 1995-03-28 Antilymphoglob

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU95104501/14A RU95104501A (en) 1995-03-28 1995-03-28 Antilymphoglob

Publications (1)

Publication Number Publication Date
RU95104501A true RU95104501A (en) 1996-12-27

Family

ID=48450929

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95104501/14A RU95104501A (en) 1995-03-28 1995-03-28 Antilymphoglob

Country Status (1)

Country Link
RU (1) RU95104501A (en)

Similar Documents

Publication Publication Date Title
RU95113492A (en) THERAPEUTIC COMBINATION CONTAINING THE HUMAN INTERFERON, ITS APPLICATION, PHARMACEUTICAL DRUG, PACKAGING AND METHOD OF TREATMENT
RU95101385A (en) Products containing g-csf and tnf-binding protein
US6720011B1 (en) Injectable composition for cancer treatment
US4501582A (en) Perfusion kit
GB2171302A (en) Therapeutic hydroxyprolines
RU95104501A (en) Antilymphoglob
Burdge et al. Neurotoxic effects during vidarabine therapy for herpes zoster.
Cuschieri et al. Kinin release after gastric surgery
ANDRUS et al. CORRECTION OF PROTHROMBIN DEFICIENCIES: BY MEANS OF 2-METHYL-1, 4-NAPHTHOQUINONE INJECTED INTRAMUSCULARLY
WAISBREN et al. Antibiotics and gamma-globulin in Pseudomonas infections
Brodsky et al. Effect of testosterone enanthate and alkylating agents on multiple myeloma
Fisher et al. The subcutaneous administration of the sodium salt of para-aminosalicylic acid in the treatment of tuberculosis
RU94016196A (en) Method for treating the cases of abdominal typhoid
Abreu et al. Interferon in experimental autoimmune encephalomyelitis: intraventricular administration
Worman et al. Hypersensitivity reaction associated with acute hepatic dysfunction following a single intravenous dose of procainamide
Currie et al. Epilepsy in dogs caused by large doses of penicillin and concurrent brain damage
FOSTER et al. THE TREATMENT OF ACUTE TYPHOID FEVER WITH CHLOROMYCETIN®
JPH0251405B2 (en)
RU2286765C1 (en) Immunomodulating agent in spray form
Hinshaw et al. Technique of streptomycin administration
Bywaters Aspects of Steroid Therapy: The Present Status of Steroid Treatment in Rheumatoid Arthritis
Silver et al. Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis-chloronitrosurea during the course of busulfan-maintained remission
JP2645554B2 (en) Miscarriage / stillbirth prevention agent
Hunter Xylocaine
KR100305044B1 (en) Therapeutics for the treatment of sickle cell anemia, malaria and exogenously induced leukopenia containing colloidal silicon oxide